Novadip Biosciences SA announces first pediatric patient with congenital pseudoarthrosis of the tibia undergoes implantation with NVD-003, an autologous tissue regeneration product, in Phase 1b/2a US/EU clinical trial Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections Paragraf acquires Cardea Bio to extend graphene electronics leadership VUV Analytics announces $20 million financing ProterixBio announces commercial offering of Quantitative Soluble ST2 Assay Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networksBack To News
May 11, 2021
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.